Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas

Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas

Abstract Background ERBB-2 is overexpressed in about 20% of breast cancers (BCs), indicating poor prognosis. The receptor activator of nuclear factor-κB (RANK) pathway is implicated in ERBB-2 (+) BC. The purpose of this study was to elucidate the underlying molecular mechanism of this interaction an...

Full description

Bibliographic Details
Main Authors: Ilianna Zoi, Michalis V. Karamouzis, Evangelia Xingi, Panagiotis Sarantis, Dimitra Thomaidou, Panayiotis Lembessis, Stamatios Theocharis, Athanasios G. Papavassiliou
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Breast Cancer Research
Subjects:
Breast cancer
RANK
RANKL
ERBB family
ERBB-2
Dimers
Online Access:https://doi.org/10.1186/s13058-019-1226-9

Internet

https://doi.org/10.1186/s13058-019-1226-9

Similar Items